Glenmark Pharmaceuticals’ Post

🙋🏻♂️ The European Hematology Association (EHA) Congress started today. It is interesting to see the number of sessions dedicated to patient centricity. Patient perspective is essential for understanding their experience along the disease journey. #EHA2024 #patientcentricity #patientadvocacy

Potential new mesothelioma drug extends survival. Integration of Pegargiminase with initial chemotherapy treatments could enhance the therapeutic results in patients suffering from nonepithelioid pleural mesothelioma, targeting to improve patient outcomes.#MesotheliomaAdvancements https://buff.ly/42Z3ZSN

New phase III study 📝 A new publication in Annals of Hematology outlines current treatments and unmet needs for patients with early/lower-risk primary #myelofibrosis and details the design of a new phase III study of ropeginterferon alfa-2b in this population, see https://loom.ly/pE6XIK0 #MPN #MPNsm

Delighted to share this short video clip discussing secondary malignancy rates in CAR-T treated patients which, Sheila and Penelope my Data Science colleagues at Medidata, will be presenting at #ASH24. This is a nice example of the types of robust clinical insights/re-affirmations of putative findings that can be gained by pooling data from many clinical trials, or by using Medidata's "Simulants" data (high-fidelity, privacy-preserving synthetic data that Medidata generates using its proprietary algorithms on pooled clinical trial data to enable robust insights from increased sample size and corresponding study power). Please feel free to share with others in your professional network, and reach out if you would like to learn more about Medidata's "Simulants" data and the types of clinically useful insights that can be extracted to inform clinical development plans/decisions or aid in clinical trial designs.

Still wondering about #theranostics and the impact of this technology for patients? Theranostics, a groundbreaking fusion of "therapy" and "diagnostics," represents a revolutionary approach to personalized medicine. The combination of using one radiopharmaceutical to identify (diagnose) and a second radiopharmaceutical to deliver therapy to treat disease has provided a unique opportunity to craft highly-specific and targeted therapies with high efficacy and great clinical impact for patients. 👉 Learn more about theranostics: #nuclearmedicine  #radiopharmaceuticals #iqmedicalservices

How can your laboratory help reduce unnecessary complications for newly diagnosed Multiple Myeloma patients? Find out how from Prof. Guy Pratt who discusses how your laboratory can help guide blood test requesting and appropriate hematology referral. Download our case studies from hospitals in the United Kingdom, United States and Spain by here: https://hubs.li/Q02phTNn0

Potential new mesothelioma drug extends survival. Integration of Pegargiminase with initial chemotherapy treatments could enhance the therapeutic results in patients suffering from nonepithelioid pleural mesothelioma, targeting to improve patient outcomes.#MesotheliomaAdvancements https://buff.ly/42Z3ZSN

In this article featured in AJMC - The American Journal of Managed Care, presenters from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition discuss outcome disparities and the burden of multiple myeloma, which remains substantially higher among Black patients than White patients. Learn more!

This guideline updates and widens the scope of the previous British Society for Hematology (BSH) Clinical guidelines for Diagnosis and Management of Heparin-Induced Thrombocytopenia (HIT): Second Edition to include functional assays in the diagnosis of HIT, when to use direct-acting oral anti-coagulants, and the role of intravenous (IV) immunoglobulins and plasma exchange in the management of HIT and spontaneous HIT. Read more from Wiley via the British Journal of Hematology: https://bit.ly/3SbnAdh | #Thrombocytopenia #PrecisionMedicine #HeparinInducedThrombocytopenia

📢The FDA has accepted, for Priority Review, the sBLA for the investigational use of isatuximab in combo with bortezomib, lenalidomide & dexamethasone (VRd) for the tx of pts with transplant-ineligible NDMM LEARN MORE➡️https://lnkd.in/gX_x522u #myeloma #multiplemyeloma #bloodcancer